Pollack, Andrew. "Study Is a Blow to Genentech's Main Product," New York Times, 9 March
1990, p. A16.
In an article related to the report of a comparative study of the clinical effectiveness of two drugs
used to dissolve blood clots in heart attack victims, T.P.A. and sterokinase, this focuses on the
reaction of the drug firm which produces the more expensive of the two substances.
Genentech, which gets $2,200 for a clinical dose of its clot dissolving drug, is reported as
"disappointed" by the Italian study's results. Indeed, its stock dropped $1.25 on the exchange.
Moreover, the stock was pulled early in the day, before trading ceased, after the results of the
study were announced. But the stock remains at $26 because investors are aware of a takeover
proposal for Genentech, which makes its stock decline resistant.
T.P.A. is one of the first commercially successful products made by genetic engineering. Now
the question becomes: are there alternative substances for the genetically engineered substances?
All the hoopla, all the money, all the promise of genetic engineering seems, here, to be in
question. Of course the particular study of this one substance proves nothing, but it does raise
some interesting doubts about the future successes of genetic engineering.